
- /
- Supported exchanges
- / US
- / PBYI.NASDAQ
Puma Biotechnology Inc (PBYI NASDAQ) stock market data APIs
Puma Biotechnology Inc Financial Data Overview
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Puma Biotechnology Inc data using free add-ons & libraries
Get Puma Biotechnology Inc Fundamental Data
Puma Biotechnology Inc Fundamental data includes:
- Net Revenue: 233 M
- EBITDA: 48 672 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-30
- EPS/Forecast: -0.22
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Puma Biotechnology Inc News

Add These 4 Top-Ranked Liquid Stocks to Boost Portfolio Returns
Investors seeking strong returns may gain by adding stocks with robust liquidity to their portfolios. Liquidity reflects a company's ability to meet its short-term financial obligations. Stocks with h...


Puma biotechnology CFO Nougues sells $33649 in stock
Maximo F. Nougues, Chief Financial Officer of Puma Biotechnology, INC. (NASDAQ:PBYI), sold a total of 9522 shares of common stock on July 8th and 9th, according to a new Form 4 filing with the Secur...

Puma biotechnology SVP Hunt sells $27624 in stock
Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, INC. (NASDAQ:PBYI), a profitable biotech company with a market cap of $175 million and strong financial health accor...

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES, July 02, 2025--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2025, the Compensation Committee of Puma’s Board of Direc...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.